EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors

Ignacio Melero, Neeltje Steeghs, Ulrik Lassen, Krisztian Homicsko, Josep Tabernero, Marta Cañamero, Andreas Roller, José Duarte, Eva Rossmann, Galina Babitzki, Nils Grabole, Carl Watson und 5 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-012885 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Ignacio Melero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Oncology and Immunology Departments, Clínica Universidad de Navarra, and CIBERONC, Pamplona, Spain imelero@unav.es. Hauptthemen laut MEDLINE: Neoplasms, Antibodies, Monoclonal, Humanized, Biomarkers, Tumor, Interleukin-2. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cergutuzumab amunaleukin (CA) is an immunocytokine comprising an anticarcinoembryonic antigen (CEA) linked to an interleukin-2 (IL-2) variant. CA does not bind to CD25 (IL-2 receptor α) and was designed to maintain the T and natural killer (NK) cell stimulatory effect, while avoiding stimulating effects on regulatory T cells (Tregs). In mouse models, CA previously demonstrated superior tumor targeting to CEA surface expression-positive (CEA+) tumors and increased CD8+ T cells and NK cell numbers in peripheral blood and tumor tissue when compared with wild-type IL-2. We present biomarker data from the first-in-human, open-label, multicenter, phase I, dose-escalation study investigating CA in patients with metastatic/unresectable CEA+ solid tumors ( NCT02004106 ).

Methods

Patients received ascending doses of CA intravenously weekly (qw: 6/10/20 mg) or every 2 weeks (q2w: 10/20/30/40 mg). Flow cytometry determined absolute numbers/mL of CD4+ and CD8+ T cells, NK cells, macrophages/monocytes, Tregs, and B cells and their expression of activation and proliferation markers in circulation. Sequential pretreatment and on-treatment paired tumor biopsies were studied by flow cytometry, multicolor immunohistochemistry, and bulk RNA sequencing. Antitumor activity was used for correlative studies.

Results

Biomarker data were collected from 55 patients. After treatment, peripheral blood samples showed increased proliferating NK cells, CD8+ T cells, and CD4+ T cells, without an apparent dose effect. Levels of circulating soluble CD25 increased in patients with intermediate/high CA doses on-treatment; levels of cytokines, such as tumor necrosis factor, also increased with high CA dose levels. On-treatment tumor samples showed increases in total and proliferating CD8+ T cells as well as CD3+ perforin+ T cells but, importantly, not in Tregs. Notably, increases in the ratio of CD8+/CD4+ T cells were more pronounced for qw than for q2w dosing, while programmed death ligand-1-positive CD14+ cells increased, particularly for the q2w schedule. Higher on-treatment circulating levels of cytokines correlated with longer progression-free survival (PFS). Apart from the positive correlation with NK cell density, no other correlations between PFS and infiltrating immune cell populations in the tumor were observed.

Conclusions

CA-induced immune pharmacodynamic effects in peripheral blood and in the tumor microenvironment without preferential Treg cell activation in patients with metastatic/unresectable CEA+ solid tumors. Trial registration number NCT02004106 ; BP28920

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntibodies, Monoclonal, HumanizedBiomarkers, TumorInterleukin-2HumansFemaleMaleMiddle AgedAgedAdultKiller Cells, Natural

Stichwörter der Autor:innen

CytokineNatural killer - NKPharmacodynamics - PDSolid tumorTumor infiltrating lymphocyte - TIL

Substanzen

Antibodies, Monoclonal, HumanizedBiomarkers, TumorInterleukin-2

Autor:innen und Institutionen

  • Oncology and Immunology Departments, Clínica Universidad de Navarra, and CIBERONC, Pamplona, Spain imelero@unav.es.
  • Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Phase 1 Unit, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Oncology, CHUV, Lausanne, Switzerland.

Förderung

  • F. Hoffmann-La Roche Ltd

Zitieren

APA

Melero, I., Steeghs, N., Lassen, U., Homicsko, K., Tabernero, J., Cañamero, M., Roller, A., Duarte, J., Rossmann, E., Babitzki, G., Grabole, N., Watson, C., Habigt, C., Evers, S., Dejardin, D., Teichgräber, V., & Charo, J. (2026). Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012885

Vancouver

Melero I, Steeghs N, Lassen U, Homicsko K, Tabernero J, Cañamero M, et al. Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-012885

BibTeX
@article{Melero2026,
  author = {Melero, Ignacio and Steeghs, Neeltje and Lassen, Ulrik and Homicsko, Krisztian and Tabernero, Josep and Cañamero, Marta and Roller, Andreas and Duarte, José and Rossmann, Eva and Babitzki, Galina and Grabole, Nils and Watson, Carl and Habigt, Christin and Evers, Stefan and Dejardin, David and Teichgräber, Volker and Charo, Jehad},
  title = {Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-012885}
}
Kostenlos starten →